

PHYSICIAN/PRACTICE LETTERHEAD

[Payer Name]

[Date]

ATTN: [Contact Title/Medical Director]

[Contact Name (if available)]

[Payer Address] [City, State ZIP]

Re: Claims Appeal Letter for COSELA™ (trilaciclib)

Patient: [Patient First and Last Name]

Date of Birth: [MM/DD/YYYY]

Subscriber ID Number: [Insurance ID Number]

Subscriber Group Number: [Insurance Group Number]

Case ID Number: [Case ID Number (if available)]

Dates of Service: [Dates]

Dear [Contact Name/Medical Director]:

I am writing on behalf of my patient, [Name of Patient], to appeal [Name of Health Insurance Company]'s decision to deny coverage for COSELA (trilaciclib) for injection, which is prescribed to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. Based on your letter of denial dated [Date], that coverage has been denied for the following reason(s), [List the Specific Reason(s) for the Denial as Stated in the Denial Letter].

Patient History and Diagnosis

[Provide a Brief Description of the Patient's Medical Condition]

[Include a Short Summary of the Patient's Medical/Medication History]

[Explain why you believe it is Medically Necessary for Patient to receive COSELA]

[Describe the Potential Consequences to the Patient if they do not receive COSELA]

[Include COSELA Indication Information]

[Include COSELA Administration Information]

Please see the accompanying enclosures and documentation demonstrating the medical necessity of COSELA. I would appreciate a prompt review of this information and authorization of COSELA. I can be reached at [provider phone number] or by fax at [provider fax number] for additional information and discussion. Thank you for your consideration.

Sincerely,

[Physician Signature]

[Physician Name and Credentials]

Enclosures: [List enclosures, which may include prescribing information, clinical notes/medical records, diagnostic test results, relevant peer-reviewed articles, relevant treatment guidelines, including NCCN®/NCCN® COVID-19/ASCO® guidelines, FDA approval letter, scans showing progressive disease, pathology reports].

REFERENCES

Cosela (trilaciclib). Prescribing information. G1 Therapeutics, Inc; 02/2021.

Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. *Int J Cancer*. 2020; Dec 21. doi: 10.1002/ijc.33453.

Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. *Adv Ther*. 2021;38:350-365.

National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version 1.2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed February 17, 2021.

NCCN® Hematopoietic Growth Factors Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2). Available at: https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf. Accessed February 17, 2021.

National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed February 17, 2021.

Smith TJ, Bohlke K, Lyman G, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33:3199-3212.

Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK 4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving first-line chemotherapy: a phase 1b/randomized phase 2 trial. *Ann Oncol*. 2019;30:1613-1621.